Drew MP. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Immunol 2012 ; 12 : 252.
Brahmer JR, Reckamp K, Baas P, et al. Nivolumab versus docetaxel in advanced squamous nonsmall cell lung cancer. N Engl J Med 2015 ; 373: 123.
Bonghaei H, Paz-Ares L, Horn L, et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med 2015 ; 373 : 1627.
Herbst RS, Baas P, Kim DW, et al. Pembrolizumab versus docetaxel for previously treated, PD-L1 positive non-small-cell lung cancer (KEYNOTE-010): a randomized controlled trial. Lancet 2015 ; 387 : 1540.